

August 22, 2024

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Sub: Chairman Speech- 31st Annual General Meeting of Orchid Pharma Limited ("the Company") held on August 21, 2024

Dear Sir/Madam,

Please find enclosed herewith the Chairman Speech as delivered at the 31st Annual General Meeting of the Company held on August 21, 2024.

Kindly take the above on your records.

Thanking you,
For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary and Compliance Officer

Encl.: as above

Chairman Speech

Dear Members,

On behalf of the Orchid Pharma Board, I would like to appreciate your support for the Company and express my gratitude for the confidences in your management.

We continue to meet digitally which enables a lot more Members participation. Your Company has done all feasible planning and execution to facilitate electronic participation and voting by the members for this AGM. I, further confirm that, the e-voting will remain accessible throughout the AGM proceedings and 15 minutes thereafter.

I will now take up the formal proceedings of the Annual General Meeting.

Let me share with you some thoughts about the Company and the macro-economic outlook with you.

Our Annual Report, inter alia, containing the Director's Report, Corporate Governance Report, Management Discussion and Analysis Report, Business Responsibility and Sustainability Report, the Notice of this AGM and the Audited Financial Statements for the financial year ended March 31, 2024 have been with you for some time now. I will, with your kind permission, take those as read.

Orchid Pharma Limited, your Company continues to be developing commercially competitive, intellectual property compliant, robust and eco-friendly technologies. The R&D thrives on 'green chemistry culture' and has developed various environment friendly & ingenious technologies, incorporating optimum atom efficiencies, recycling and reuse of solvents/reagents/by-products targeting towards zero discharge of effluents, removal/substitution/ minimisation of hazardous chemicals and replacing chemical processes with enzymatic/ chemo catalysis processes.

In the same direction, your company has achieved a significant breakthrough in registration of Enmetazobactam: *A Landmark achievement for India's Pharmaceutical Industry.*

Orchid is the only Indian Company, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA. Further, the European Medicines Agency have also granted approval to Orchid's newly invented - Enmetazobactam. The primary novel invention component of ORBLICEF - Enmetazobactam is the first drug invented in India to have achieved this landmark. Due to the new invention of your Company, it stands out at the global stage of Pharmaceutical Market.

In a significant move to address the global need for affordable and efficacious drugs to combat Anti- Microbial Resistance (AMR), the recent approval of CDSCO has paved the way for launch in India. As the issue of Anti-Microbial Resistance is very serious in India, this therapy will be a very important solution in the hands of the clinicians across the country. Your Company is ready to launch ORBLICEF, our brand name for the Enmetazobactam + Cefepime combination, which stands for "Orchid's Beta-Lactamase-Inhibitor + Cefepime." We are confident that this product will make a significant impact in the market, and to augment its reach, we have signed a marketing agreement with CIPLA. This partnership will ensure that ORBLICEF reaches a broad audience and achieves its full market potential.

On the Financial highlights of Orchid's journey through the F.Y. 2024, I would like to brief you in short about the financial numbers which has been already shared with you.

- The Revenue for the F.Y. 2023-24 was Rs.849 Crores as against Rs.685 Crores in the previous year. For the same period the EBITDA was Rs.142 Crores as against Rs.103 Crores in the previous year.
- The year-on-year growth is 23%, in revenue and the growth on EBITDA is 36% approx.

Regarding our ongoing projects, I am pleased to report that land acquisition for our 7ACA project is 95% complete. We are planning to break ground on this project on the auspicious day of Ganesh Chaturthi. This is a significant milestone for us, and we are excited to take this important step forward.

I would like to take this opportunity to express my sincere appreciation for the support of all our stakeholders including Employees, customers, suppliers, service providers, medical fraternity and business partners, Central and State Government, Statutory Authorities and the Central Drugs Standard Control Organization and State Food Safety and Drugs Administration (State FDAs).

With all the confidence and support, of the stakeholders, I feel very optimistic about Orchid Pharma.

Finally, I thank my fellow board members for their valuable guidance and contributions to the Company's management and the management team and our employees for their efforts in building your Company's future.

Thank you all for your continued support.